Photo from wikipedia
Accelerated drug development for diseases with high unmet need demands patient focus without compromising scientific rigor. Precision dosing informed by physiologically-based pharmacokinetic (PBPK) models will enable inclusive clinical trials and… Click to show full abstract
Accelerated drug development for diseases with high unmet need demands patient focus without compromising scientific rigor. Precision dosing informed by physiologically-based pharmacokinetic (PBPK) models will enable inclusive clinical trials and narrow the gap between clinical development and realworld use. Early incorporation of the mass balance (MB) study is crucial to maximize the fidelity of a PBPK model-informed approach to precision dosing across populations and contexts of use in clinical development and therapeutic use.
Journal Title: Clinical Pharmacology and Therapeutics
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!